BackgroundRheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) are diseases where inflammation plays a key role in their development and have an increased risk of developing comorbid conditions. It is important to evaluate the comorbidities associated with these diseases.ObjectivesOur objective was to evaluate the prevalence of comorbidities in RA, PsA and axSpA patients from the PANLAR´s register of rheumatic diseases (PANRED).MethodsPANRED includes real world data from Latin American consecutive patients diagnosed with RA, PsA and axSpA (ACR-EULAR 2010/CASPAR 2006-ASAS 2009) from Dec 2021 to Dec 2022. We collected: demographics, disease characteristics (activity, severity, treatment), basal comorbidities (cardiovascular, infections, cancer, gastrointestinal, pulmonary, and others) data. Data were extracted from patients initiating treatment with cDMARDS, TNF alpha inhibitors (TNFi) and Jakinasas inhibitors (JAKi). Categorical variables were expressed as percentage and tables of contingency were analyzed with χ2 or Fisher test. A p value less than 0.05 was considered significant.Results708 patients were included. RA was the most frequent disease. The most prevalent comorbidities expressed as overall frequency were: hypertension: 39.5%, nonalcoholic steatohepatitis: 35.6%, dyslipidemia: 35.3%, tuberculosis 13.3%. Details of comorbidities are shown in the Table 1. Uveitis was more frequent in axSpA vs RA, RR: 2.5 (95%CI 1.35-4.8), p<0.001. Herpes zoster was present in 3.3%, 3.6% and 0.8% and tuberculosis in 15.85%, 15.1% and 3.8% in Jaki, TNFi and cDMARD groups respectively. Steatohepatitis was significantly higher in the cDMARD group compared Jaki and TNFi (p=0.01) and tuberculosis in the JAKi group (p=0.002) compared bDMARD and cDMARD, as basal characteristics, probably reflecting therapeutic decisions.ConclusionCardiovascular comorbidities and tuberculosis are frequent in Latin American patients and should be considered in treatment selection.Table 1.Prevalence of comorbidities.Total (N=708)RA(N= 632)(89.3%)PsA(N= 32)(4.5%)axSpA(N = 38)(5.4%)Other(N = 6)(0.8%)Hypertension39.5%40.6%34.4%27%33.3%Stroke1%1.1%000Acute myocardial infarction2.3%2.6%000Dyslipidemia35.3%36.5%34.4%18.9%16.7%Smoking23.5%CS: 41.4%EX: 58.6%23.7%CS:39%Ex: 61%34.4%CS: 63.6%Ex: 36.4%15.3%CS: 60%Ex: 40%0Diabetes13.6%Tipe II: 95.8%14.52%Tipe II: 13.86%15.6%Tipe II: 100%5.4%Tipe II: 100%0Non-cutaneous cancers plus melanomas2.4%2.4%3.1%2.7%0Non-melanoma skin cancers0.7%0.6%02.7%0Inflammatory bowel disease0.6%0.5%02.7%0Nonalcoholic steatohepatitis35.6%5.5%12.9%2.7%0Uveitis2.3%1%027%0Deep venous thrombosis (DVT or PT)2.3%DVT: 68.75%TVP + PT: 31.25%2.6%DVT: 68.75%DVT+PT:31.25%000Herpes Zoster3.7%MC: 100%3.9%MC: 100%3.1%MC: 100%2.7%MC: 100%0COPD3.3%3.4%3.1%2.7%0Interstitial lung disease5.48%UIP:47.4%NSIP:34.2%5.98%UIP: 48.6%NSIP: 35.1%3.1%00Tuberculosis13.3%Latent: 79.34%AP: 16.3%A-ExP: 4.36%13.3%Latent:78%AP: 17.1%A-ExP: 4.9%12.5%Latent:75%%AP: 25%%A-ExP: 0%16.2%Latent: 100%AP: 0%A-ExP: 0%0Hepatitis B2%1.9%3.1%2.7%0Hepatitis C0.7%0.6%3.1%00HIV0.3%0.3%000Chagas0.7%0.6%3.1%00Current smoking: CS; pulmonary throboembolism: PT; deep venous thrombosis: DVT; monometameric cutaneous: MC; chronic obstructive pulmonary disease: COPD; active pulmonary: AP; A-ExP: Active Extrapulmonary.REFERENCES:NIL.Acknowledgements:NIL.Disclosure of InterestsEnrique Soriano Speakers bureau: Speaker, consulting, or research support: Abbvie, Amgen, Bristol Myers-Squibb, Janssen, Elli-Lilly, Novartis, Pfizer, Roche, Sandoz, UCB., Consultant of: Speaker, consulting, or research support: Abbvie, Amgen, Bristol Myers-Squibb, Janssen, Elli-Lilly, Novartis, Pfizer, Roche, Sandoz, UCB., Grant/research support from: Speaker, consulting, or research support: Abbvie, Amgen, Bristol Myers-Squibb, Janssen, Elli-Lilly, Novartis, Pfizer, Roche, Sandoz, UCB., Nicolas Marin Zucaro: None declared, Gilda Ferreira: None declared, GABRIEL MACIEL: None declared, Ariana Ringer: None declared, Pedro Santos-Moreno: None declared, Norberto Javier Quagliato: None declared, B Stadler: None declared, Ana Cristina De Mereiros Ribeiro: None declared, Claiton Brenol: None declared, Vander Fernandes: None declared, LUISA SERVIOLI: None declared, Rina Giorgi: None declared, cristiano lupo: None declared, Ana Cristina Medeiros-Ribeiro: None declared, S Studart: None declared, Ines Guimaraes Silveira: None declared, Manuella Lima Gomes Octrop: None declared, Daniel G. Fernández-Ávila Consultant of: Fernández-Ávila, DG. Consulting: Abbvie, Bristol Myers-Squibb, Elli-Lilly, Fresenius kabi, Janssen, Novartis, Pfizer., Maria Lorena Brance: None declared.